Skip to main content
SpringerLink
Log in

Design of Clinical Trials for Anti-Angiogenics

  • Chapter
The New Angiotherapy

Abstract

The development of new treatment programs is fraught frequently with similar conundrums. The backbone of the Hippocratic Oath, “First do no harm,” counsels the clinical investigator to discover the safest mode, schedule, and dose for treatment administration. The requirement to treat the disease drives identification of the optimal schedule, trial endpoints, and analytic approaches. These same questions must be satisfied in order to bring new clinical interventions to the general community whether the pathology is systemic, such as in diabetes and cancer, or focal, as seen in epilepsy and appendicitis. These are the questions with which the new discipline of angiotherapy is now faced. The following issues will be discussed in the context of the development of anti-angiogenic agents for cancer treatment as the paradigm.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Zelen, M. (1997) Theory and practice of clinical trials, in Cancer Medicine ( Holland, J. F., et al., eds.), Williams and Wilkins, Baltimore, MD, pp. 423–436.

    Google Scholar 

  2. Holland, J. F., Frei, E., Kufe, D., and Bast, R. C. (1997) Principles of medical oncology, in Cancer Medicine ( Holland, J. F., et al., eds.), Williams and Wilkins, Baltimore, MD, pp. 755–765.

    Google Scholar 

  3. Labianca, R., Pancera, G., Dallavalle, G., Pessi, A., and Zamparelli, G. (1997) Response evaluation as the key-point in results interpretation. Tumori 83 (Suppl.), S73 — S76.

    CAS  PubMed  Google Scholar 

  4. Frei, E. and Antman, K. (1997) Combination chemotherapy, dose and schedule, in Cancer Medicine ( Holland, J. F., et al., eds.), Williams and Wilkins, Baltimore, MD, pp. 817–838.

    Google Scholar 

  5. Motzer, R. J., Reed, E., Perera, F., Tang, D., Shamkhani, H., Poirier, M. C., et al. (1994) Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay. Cancer 73, 2843–2852.

    Article  CAS  PubMed  Google Scholar 

  6. Benchekroun, M. N., Parker, R., Dabholkar, M., Reed, E., and Sinha, B. K. (1995) Effects of interleukin-1 alpha on DNA repair in human ovarian carcinoma (NIH:OVCAR-3) cells: implications in the mechanism of sensitization of cis-diamminedichloroplatinum(II). Mol. Pharmacol 47, 1255–1260.

    CAS  PubMed  Google Scholar 

  7. Sancar, A. (1995) DNA repair in humans. Annu. Rev. Genet. 29, 69–105.

    Article  CAS  PubMed  Google Scholar 

  8. Ratain, M. and Plunkett, W. (1997) Pharmacology, in Cancer Medicine ( Holland, J. F., et al., eds.), Williams and Wilkins, Baltimore, MD, pp. 875–890.

    Google Scholar 

  9. Klauber, N., Parangi, S., Flynn, E., Hamel, E., and D’Amato, R. J. (1997) Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 57, 81–86.

    CAS  PubMed  Google Scholar 

  10. Kohn, E. C., Sandeen, M. A., and Liotta, L. A. (1992) In vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium, arachidonate, and inositol phosphates. Cancer Res. 52, 3208–3212.

    CAS  PubMed  Google Scholar 

  11. Kohn, E. C. and Liotta, L. A. (1995) Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res. 55, 1856–1862.

    CAS  PubMed  Google Scholar 

  12. Schipper, H., Goh, C. R., and Wang, T. L. (1995) Shifting the cancer paradigm: must we kill to cure? J. Clin. Oncol. 13, 801–807.

    CAS  PubMed  Google Scholar 

  13. Folkman, J. (1971) Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 285, 1182–1186.

    Article  CAS  PubMed  Google Scholar 

  14. Folkman, J. and Shing, Y. (1992) Angiogenesis. J. Biol. Chem. 267, 10931.

    CAS  PubMed  Google Scholar 

  15. Liotta, L. A. and Steeg, P. S. (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64, 327.

    Article  CAS  PubMed  Google Scholar 

  16. Folkman, J., Hochberg, M., and Knighton, D. (1974) Self-regulation of growth in three dimensions: the role of surface area limitations, in Control of Proliferation in Animal Cells ( Clarkson B. and Baserga, R., eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 833–842.

    Google Scholar 

  17. Folkman, J., Karol, W., Ingber, D., and Hanahan, D. (1989) Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339, 58–61.

    Article  CAS  PubMed  Google Scholar 

  18. Holmgren, L., O’Reilly, M. S., and Folkman, J. (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression {see comments]. Nature Med. 1, 149–153.

    Article  CAS  PubMed  Google Scholar 

  19. Kohn, E. C., Alessandro, R., Spoonster, J., Wersto, R., and Liotta, L. A. (1995) Angiogenesis: role of calcium-mediated signal transduction. Proc. Natl. Acad. Sci. USA 92, 1307–1311.

    Article  CAS  PubMed  Google Scholar 

  20. Kohn, E. C., Figg, W. D., Sarosy, G. A., Bauer, K. S., Davis, P. A., Soltis, M. J., et al. (1997) Phase I trial of micronized formulation CAI in patients with refractory solid tumors: pharmacokinetics, clinical outcome and comparison of formulations. J. Clin. Oncol. 15, 1985–1993.

    CAS  PubMed  Google Scholar 

  21. D’Amato, R., Loughnan, M., Flynn, E., and Folkman, J. (1994) Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA 91, 4082–4085.

    Article  PubMed  Google Scholar 

  22. Pluda, J. M. (1997) Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin. Oncol. 24, 203–218.

    CAS  PubMed  Google Scholar 

  23. Gasparini, G. and Presta, M. (1996) Clinical studies with angiogenesis inhibitors: biologic rationale and challenges for their evaluation. Ann. Oncol. 7, 441–444.

    Article  CAS  PubMed  Google Scholar 

  24. Liotta, L. A., Kleinerman, J., and Saidel, G. (1974) QuantitatiVe relationships of intravascular tumor cells: tumor vessels and pulmonary metastases following tumor implantation. Cancer Res. 34, 997–1003.

    CAS  PubMed  Google Scholar 

  25. Weidner, N., Semple, J. P., Welch, W. R., and Folkman, J. (1991) Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med. 324, 1–8.

    Article  CAS  PubMed  Google Scholar 

  26. Hanahan, D. and Folkman, J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353–364.

    Article  CAS  PubMed  Google Scholar 

  27. Zarnegar, R. (1995) Regulation of HGF and HGFR gene expression. EXS 74, 33–49.

    CAS  PubMed  Google Scholar 

  28. Rosen, E. M. and Goldberg, I. D. (1997) Regulation of angiogenesis by scatter factor. EXS 79, 193–208.

    CAS  PubMed  Google Scholar 

  29. Polverini, P. J. and Nickoloff, B. J. (1995) The role of scatter factor and the c-met proto-oncogene in angiogenic responses. EXS 74, 51–67.

    CAS  PubMed  Google Scholar 

  30. Wang, Y. J., Shahrokh, Z., Vemuri, S., Eberlein, G., Beylin, I., and Busch, M. (1996) Characterization, stability, and formulations of basic fibroblast growth factor. Pharm. Biotechnol. 9, 141–180.

    Article  CAS  PubMed  Google Scholar 

  31. Burgess, W. H. and Maciag, T. (1989) The heparin-binding (fibroblast) growth factor family of proteins. Annu. Rev. Biochem. 58, 575–606.

    Article  CAS  PubMed  Google Scholar 

  32. Bikfalvi, A., Klein, S., Pintucci, G., and Rifkin, D B (1997) Biological roles of fibroblast growth factor-2. Endocr. Rev. 18, 26–45.

    Article  CAS  PubMed  Google Scholar 

  33. Mignatti, P., Tsuboi, R., Robbins, E., and Rivkin, D. B. (1989) In vitro angiogenesis on the human amniotic membrane: Requirement for basic fibroblast growth factor-induced proteinases. J. Cell Biol. 108, 671–682.

    Article  CAS  PubMed  Google Scholar 

  34. Sato, Y. and Rifkin, D. B. (1988) Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. J. Cell. Biol. 107, 1199–1205.

    Article  CAS  PubMed  Google Scholar 

  35. Plate, K. H., Breier, G., Weich, H. A., Mennel, H. D., and Risau, W. (1994) Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein, and possible in vivo regulatory mechanisms. Int. J. Cancer 59, 520–529.

    Article  CAS  PubMed  Google Scholar 

  36. Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., and Ferrara, N. (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362, 841–844.

    Article  CAS  PubMed  Google Scholar 

  37. Ferrara, N., Houck, K., Jakeman, L., and Leung, D. W. (1992) Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr. Rev. 13, 18–32.

    CAS  PubMed  Google Scholar 

  38. Miller, J. W., Atlantis, A. P., and Aiello, L. P. (1997) Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab. Rev. 13, 37–50.

    Article  CAS  PubMed  Google Scholar 

  39. Takahashi, Y., Kitadai, Y., Bucana, C. D., Cleary, K. R., and Ellis, L. M. (1995) Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 55, 3964–3968.

    CAS  PubMed  Google Scholar 

  40. Furcht, L. (1986) Critical factors controlling angiogenesis: cell products, cell matrix, and growth factor. Lab. Invest 5, 505–509.

    Google Scholar 

  41. Aaronson, S. A. (1991) Growth factors and cancer. Science 254, 1146–1153.

    Article  CAS  PubMed  Google Scholar 

  42. Bussolino, F., Albini, A., Camussi, G., Presta, M., Viglietto, G., Ziche, M., and Persico, G. (1996) Role of soluble mediators in angiogenesis. Eur. J. Cancer 32A, 2401–2412.

    Article  Google Scholar 

  43. Klein, S., Roghani, M., and Rifkin, D. B. (1997) Fibroblast growth factors as angiogenesis factors: new insights into their mechanism of action. EXS 79, 159–192.

    CAS  PubMed  Google Scholar 

  44. Kohn, E. C., Felder, C. C., Jacobs, W., Holmes, K. A., Day, A. F., Freer, R., and Liotta, L. A. (1994) Stucture function analysis of signal and growth inhibition by carboxyamido-triazole, CAI. Cancer Res. 54, 935–942.

    CAS  PubMed  Google Scholar 

  45. Kohn, E. C.,Jacobs, W., Kim, Y. S., Alessandro, R., Stetler-Stevenson, W. G., and Liotta, L. A. (1994) Calcium influx modulates expression of matrix metalloproteinase-2 (72 kDa type IV collagenase, gelatinase A) expression. J. Biol. Chem. 269, 21,505–21,511.

    Google Scholar 

  46. Taraboletti, G., Garofalo, A., Belotti, D., Drudis, T., Borsotti, P., Scanziani, E., et al. (1995) Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J. Natl. Cancer Inst. 87, 293–298.

    Article  CAS  PubMed  Google Scholar 

  47. Galardy, R., Grobelney, D., Foellmer, H. G., and Fernandez, L. A. (1994) Inhibition of angiogenesis by the matrix metalloprotease inhibitorN-{2R-2-(hydroxamidocarbonymethyl)-4 methylpentanoyl)]L-tryptophan methylamide. Cancer Res. 54, 4715–4718.

    CAS  PubMed  Google Scholar 

  48. Eccles, S. A., Box, G. M., Court, W. J., Bone, E. A., Thomas, W., and Brown, P. D. (1996) Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res. 56, 2815–2822.

    CAS  PubMed  Google Scholar 

  49. Brown, P. D. and Giavazzi, R. (1995) Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann. Oncol. 6, 967–974.

    CAS  PubMed  Google Scholar 

  50. Folkman, J. (1995) Angiogenesis inhibitors generated by tumors. Mol. Med. 120–122.

    Google Scholar 

  51. O’Reilly, M. S., Holmgren, L., Chen, C., and Folkman, J. (1996) Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med. 2, 689–692.

    Article  PubMed  Google Scholar 

  52. O’Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., et al. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277–285.

    Article  PubMed  Google Scholar 

  53. Fidler, I. J. and Hart, I. R. (1982) Biologic diversity in metastatic neoplasms–origins and implications. Science 217, 998–1001.

    Article  CAS  PubMed  Google Scholar 

  54. Gimbrone, M. A. J., Leapman, S. B., Cotran, R. S., and Folkman, J. (1973) Tumor angiogenesis: iris neovascularization at a distance from experimental intraocular tumors. J. Natl. Cancer Inst. 50, 219–228.

    PubMed  Google Scholar 

  55. Gimbrone, M. A., Leapman, S. B., Cotran, R. S., and Folkman, J. (1972) Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med. 136, 261–276.

    Article  PubMed  Google Scholar 

  56. Nguyen, M., Watanabe, H., and Budson, A. E. (1994) Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J. Natl. Cancer Inst. 86, 356–361.

    Article  CAS  PubMed  Google Scholar 

  57. Price, J. T., Bonovich, M. T., and Kohn, E. C. (1997) The biochemistry of cancer dissemination. Crit. Rev. Biochem. Mol. Biol. 32, 175–253.

    Article  CAS  PubMed  Google Scholar 

  58. Goldie, J. H. and Coldman, A. J. (1986) Application of theoretical models to chemotherapy protocol design. Can. Treat Rep. 70, 127–131.

    CAS  Google Scholar 

  59. Norton, L. and Simon, R. (1977) Tumor size, sensitivity to therapy, and the design of treatment schedules. Can. Treat Rep. 61, 1307.

    CAS  Google Scholar 

  60. Folkman, J. (1996) Fighting cancer by attacking its blood supply. Scientific American, 150–154.

    Google Scholar 

  61. Teicher, B. A., Holden, S. A., Ara, G., Korbut, T., and Menon, K. (1996) Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma. Cancer Chemother. Pharmacol. 38, 169–177.

    Article  CAS  PubMed  Google Scholar 

  62. Eckardt, J., Eckardt, G., Villalona-Calero, M., Drengler, R., and Von Hoff, D. (1995) New anticancer agents in clinical development. Oncology 9, 1321–1328.

    CAS  PubMed  Google Scholar 

  63. Tanaka, Y., Kawamata, H., Fujimoto, K., and Oyasu, R. (1997) Angiogenesis inhibitor TNP-470 suppresses tumorigenesis in rat urinary bladder. J. Urol. 157, 683–688.

    Article  CAS  PubMed  Google Scholar 

  64. Yamaoka, M., Yamamoto, T., Ikeyama, A., Sudo, K., and Fumita, T. (1993) Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res. 53, 5233–5236.

    CAS  PubMed  Google Scholar 

  65. Fan, T.-P. D. and Brem, S. (1992) Angiosuppression, in The Search for New Anti-Cancer Drugs (Waring, M. J. and Ponder, B. A. J., eds.), Kluwer Academic Publishers, Lancaster, U. K., pp. 185–229.

    Google Scholar 

  66. Teicher, B. A., Holden, S. A., Ara, G., Sotomayor, E. A., Huang, Z. D., Chen, Y. N., and Brem, H. (1994) Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int. J. Cancer 57, 920–925.

    Article  CAS  PubMed  Google Scholar 

  67. Teicher, B. A., Holden, S. A., Dupuis, N. P., Kakeji, Y., Ikebe, M., Emi, Y., and Goff, D. (1995) Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. Breast Cancer Res. Treat. 36, 227–236.

    Article  CAS  PubMed  Google Scholar 

  68. Pluda, J. M. and Parkinson, D. R. (1996) Clinical implications of tumor-associated neovascularization and current antiangiogenic strategies for the treatment of malignancies of pancreas. Cancer78,680–687.

    Google Scholar 

  69. Hawkins, M. J. (1995) Clinical trials of antiangiogenic agents. Curr. Opin. Oncol. 7, 90–93.

    CAS  PubMed  Google Scholar 

  70. Kensler, T. W. and Groopman, J. D. (1996) Carcinogen-DNA and protein adducts: biomarkers for cohort selection and modifiable endpoints for chemoprevention trials. J. Cell. Biochem. 255, 85–91.

    Article  Google Scholar 

  71. Mark, S. D. (1996) Defining and analyzing cohorts using molecular markers of cancer risk. J. Cell. Biochem. 255, 69–79.

    Article  Google Scholar 

  72. Zucker, S., Lysik, R. M., DiMassimo, B. I., Zarrabi, H. M., Moll, U. M., Grimson, R., et al. (1995) Plasma assay of gelatinase B: tissue inhibitor of metalloproteinase complexes in cancer. Cancer 76, 700–708.

    Article  CAS  PubMed  Google Scholar 

  73. Bostwick, D. G., Burke, H. B., Wheeler, T. M., Chung, L. W. K., Bookstein, R., Pretlow, T. G., et al. (1994) The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials. J. Cell. Biochem. 19 (Suppl.), 283–289.

    CAS  Google Scholar 

  74. Hawighorst, H., Knapstein, P. G., Knopp, M. V., Weikel, W., Brix, G., Zuna, I., et al. (1998) Uterine cervical carcinoma: comparison of standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival. Cancer Res. 58, 3598–3602.

    CAS  PubMed  Google Scholar 

  75. Hawighorst, H.,Knapstein, P. G., Weikel, W., Knopp, M. V., Zuna, I.,Knof, A., et al. (1997) Angiogenesis of uterine cervical carcinoma: characterization by pharmacokinetic magnetic resonance parameters and histological microvessel density with correlation to lymphatic involvement. Cancer Res. 57,4777–4786.

    Google Scholar 

  76. Weidner, N. and Folkman, J. (1996) Tumor vascularity as a prognostic factor in cancer, in Important advances in Oncology 1996 ( DeVita, V. T., Hellman, S., and Rosenberg, S. A., eds.), Lippincott-Raven, Philadelphia, PA, pp. 167–190.

    Google Scholar 

  77. Hollingsworth, H. C. C. K. E., Steinberg, S. M., Rothenberg, M. L., and Merino, M. J. (1995) Tumor angiogenesis in advanced stage ovarian carcinoma. Am. J. Pathol. 147, 9–19.

    Google Scholar 

  78. Zucker, S., Lysik, R. M., Zarrabi, H. M., Moll, U., Tickle, S. P., Stetler-Stevenson, W., et al. (1994) Plasma assay of matrix metalloproteinases (MMPs) and MMP-inhibitor complexes in cancer. Potential use in predicting metastasis and monitoring treatment. Ann. NYAcad. Sci. 732, 248–2062.

    Google Scholar 

  79. Koukourakis, M. I., Giatromanolaki, A., Thorpe, P. E., Brekken, R. A., Sivridis, E., Kakolyris, S., et al. (2000) Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res. 60, 3088–3095.

    Google Scholar 

  80. McBride, W. (1968) Thalidomide and congenital abnormalities. Lancet 2, 1358.

    Google Scholar 

  81. Lenz, W. (1962) Thalidomide and congenital abnormalities. Lancet i, 45–46.

    Google Scholar 

  82. Figg, W. D., Bergan, R., Brawley, O., Tompkins, A., Linchan, M., Duray, P., et al. (1997) Randomized Phase II study of thalidomide in androgen independent prostate cancer. Proc. ASCO 16, 333a.

    Google Scholar 

  83. Fine, H. A., Loeffler, J. S., Kyritsis, A., Wen, P., Black, P. M., Levin, V. A., et al. (1997) A phase I trial of the anti-angiogenic agent, thalidomide, in patients with recurrent high grade gliomas. Proc. ASCO 16, 385a.

    Google Scholar 

  84. Fullerton, P. M. and O’Sullivan, D. J. (1968) Thalidomide neuropathy: a clinical, electrophysiological, and histological follow-up study. J. Neuro. Neurosurg. Psychiatr. 31, 543–551.

    Article  CAS  Google Scholar 

  85. Jacobson, J. M., Greenspan, J. S., Spritzler, J., Ketter, N., Fahey, J. L., Jackson, J. B., et al. (1997) Thalidomide for the treatment of oral aphthous ulcers in patients with human innumodeficiency virus infection. N. Engl. J. Med. 336, 1487–1493.

    Article  CAS  PubMed  Google Scholar 

  86. Kohn, E. C., Reed, E., Sarosy, G., Christian, M., Link, C J, Cole, K., et al. (1996) Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res. 56, 569–573.

    CAS  PubMed  Google Scholar 

  87. Berlin, J., Tutsch, K., Hutson, P., Cleary, J., Rago, R. P., Arzoomanian, R. Z., et al. (1997) Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor. J. Clin. Oncol. 15, 781–789.

    CAS  PubMed  Google Scholar 

  88. Thiabault, A., Samid, D., Tompkins, A. C., Figg, W. D., Cooper, M. R., Hohl, R. J., et al. (1996) Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin. Cancer Res. 2, 483–491.

    Google Scholar 

  89. Oliver, S. J., Banquerigo, M. L., and Brahn, E. (1994) Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol. Cell Immunol. 157, 291–299.

    Article  CAS  PubMed  Google Scholar 

  90. Teicher, B. A., Holden, S. A., Chen, Y. N., Ara, G., Korbut, T. T., and Northey, D. (1994) CAI: effects on cytotoxic therapies in vitro and in vivo. Cancer Chemother. Pharmacol. 34, 515–521.

    Article  CAS  PubMed  Google Scholar 

  91. Teicher, B. A., Ara, G., Menon, K., and Schaub, R. G. (1996) In vivo studies with interleukin-12 alone and in combination with monocyte colony-stimulating factor and/or fractionated radiation treatment. Int. J. Cancer 65, 80–84.

    Article  CAS  PubMed  Google Scholar 

  92. Zhang, Y., Griffith, E. C., Sage, J., Jacks, T., and Liu, J. O. (2000) Cell cycle inhibition by the antiangiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. Proc. Natl. Acad. Sci. USA 97, 6427–6432.

    Article  CAS  PubMed  Google Scholar 

  93. Alessandro, R., Masiero, L., Liotta, L. A., and Kohn, E. C. (1996) The role of calcium in the regulation of invasion and angiogenesis. In vivo 10, 153–160.

    CAS  PubMed  Google Scholar 

  94. Felder, C. C., Ma, A. L., Liotta, L. A., and Kohn, E. C. (1991) The antiproliferative and antimetastatic compound L651582, inhibits muscarinic acetylcholine receptor-stimulated calcium influx and arachidonic acid release. J. Pharm. Exp. Ther. 257, 967–971.

    CAS  Google Scholar 

  95. Masiero, L., Lapidos, K. A., Ambudkar, I., and Kohn, E. C. (1999) Regulation of the RhoA pathway in human endothelial cell spreading on type IV collagen: role of calcium influx. J. Cell Sci. 112, 3205–3213.

    Google Scholar 

  96. Taki, T., Ohnishi, T., Arita, N., Hiraga, S., Saitoh, Y., Izumoto, S., et al. (1994) Anti-proliferative effects of TNP-470 on human malignant glioma in vivo: potent inhibition of tumor angiogenesis. J. Neuroonc. 19, 251–258.

    Article  CAS  Google Scholar 

  97. Hori, A., Ikeyama, S., and Sudo, K. (1994) Suppression of cyclin D1 mRNA expression by the angiogenesis inhibitor TNP-470 (AGM-1470) in vascular endothelial cells. Biochem. Biophys. Res. Comm. 204, 1067–1073.

    Article  CAS  PubMed  Google Scholar 

  98. Angiolillo, A. L., Sgadari, C., Taub, D. D., Liao, F., Farber, J. M., Maheshwari, S., et al. (1995) Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med. 182, 155–162.

    Article  CAS  PubMed  Google Scholar 

  99. Lamers, C., Gratama, J., Ogilvie, A., Goey, H., Druit, W., Peschel, C., et al. (1997) Exogenous IL-12 induces in vivo IL-10 production, followed by downregulation of IL-12 activities. Proc. ASCO 16, 435a.

    Google Scholar 

  100. Voest, E. E., Kenyon, B. M., O’Reilly, M. S., Truitt, G., D’ Amato, R. J., and Folkman, J. (1995) Inhibition of angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst. 87, 581–586.

    Article  CAS  PubMed  Google Scholar 

  101. Wang, X., Fu, X., Brown, P. D., Crimmin, M. J., and Hoffman, R. M. (1994) Matrix metalloproteinase inhibitor BB-94 (Batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res. 54, 4726–4728.

    CAS  PubMed  Google Scholar 

  102. Wamil, B. D., Thurman, G. B., Sundell, H. W., DeVore, R. F., Wakefield, G., Johnson, D. H., et al. (1997) Soluble E-selectin in cancer patients as a marker of the therapeutic efficacy of CM 101, a tumor-inhibiting anti-neovascularization agents, evaluated in phase 1 clinical trial. J. Cancer Res. Clin. Oncol. 123, 173–179.

    Article  CAS  PubMed  Google Scholar 

  103. Gutierrez-Rodriguez, O., Starusta-Bacal, P., and Gutierrez-Montes, O. (1989) Treatment of refractory rheumatoid arthritis–the thalidomide experience. J. Rheumatol. 16, 158–163.

    CAS  PubMed  Google Scholar 

  104. Ochonisky, S., Verroust, J., Bastuju-Garin, S., Cherardi, R., and Revus, J. (1994) Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. Arch. Dermatol. 130, 66–69.

    Article  CAS  PubMed  Google Scholar 

  105. Bukowski, R. M., Olencki, T., Sandstrom, K., Schwartz, L., Berg, W., Huber, M., et al. (1997) Phase I trial of subcutaneous interleukin-12 in patients with metastatic renal cell carcinoma. Proc. ASCO 16, 108a.

    Google Scholar 

  106. Brown, P. D. (1994) Preclinical and clinical studies on the matrix metalloproteinase inhibitor, batimastat (BB94). Clin. Exp. Metastasis 12, 23.

    Google Scholar 

  107. Bodurtha, A., Eisenhauer, E., Steward, W., Rusthoven, J., Qirt, I., Lohmann, R., et al. (1997) Phase I-II study of marimastat (BB2516) in patients with metastatic melanoma. Proc. Am. Soc. Clin. Oncol. 16, 493a.

    Google Scholar 

  108. Rasmussen, H., Rugg, T., Brown, P., Baillet, M., and Millar, A. (1997) A 371 patient meta-analysis of studies of marimastat in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. 16, 429a.

    Google Scholar 

  109. Dezube, B. J., Von Roenn, J. H., Holden-Wiltse, J., Remick, S., Cooley, T. P., Cheung, T. W., et al. (1997) Fumagillin analog (TNP-470) in the treatment of Kaposi’s sarcoma- A phase AIDS clinical trial group study. Proc. Natl. AIDS Malignancy Conf A35.

    Google Scholar 

  110. Pluda, J. M., Lietzau, J., and Wyvill, K. (1993) A Phase-I Trial administering TNP-470 (AGM-1470) to patients with HIV- associated Kaposi’s syndrome (abstr.) Proc. 1st Natl. Conf. Human Retroviruses Related Infect. 1, 61.

    Google Scholar 

  111. Pluda, J. M., Wyvill, K., and Figg, W. D. (1994) A Phase I study of an angiogenesis inhibitor, TNP-470 (AGM-1470), administered to patients with HIV-associated Kaposi’s sarcoma (abstr.) Proc. ASCO 13, 8.

    Google Scholar 

Download references

Authors
  1. Elise C. Kohn
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Angiogenesis Laboratory, Department of Pharmacology, University of Cambridge, Cambridge, UK

    Tai-Ping D. Fan PhD

  2. Molecular Signaling Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

    Elise C. Kohn MD (Chief) (Chief)

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media New York

About this chapter

Cite this chapter

Kohn, E.C. (2002). Design of Clinical Trials for Anti-Angiogenics. In: Fan, TP.D., Kohn, E.C. (eds) The New Angiotherapy. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-126-8_28

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-126-8_28

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9657-4

  • Online ISBN: 978-1-59259-126-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation